<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077493</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000352020</org_study_id>
    <secondary_id>NCI-04-C-0079H</secondary_id>
    <secondary_id>NCI-5643</secondary_id>
    <nct_id>NCT00077493</nct_id>
    <nct_alias>NCT00075309</nct_alias>
  </id_info>
  <brief_title>BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge Antibody Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal&#xD;
      cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute&#xD;
      lymphoblastic leukemia and non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in&#xD;
      treating young patients with relapsed or refractory acute lymphoblastic leukemia or&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxic effects of BL22 immunotoxin in pediatric patients with relapsed or&#xD;
           refractory CD22-positive acute lymphoblastic leukemia or non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Determine the immunogenicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the in vitro cytotoxicity of this drug against lymphoblasts from patients with&#xD;
           acute lymphoblastic leukemia.&#xD;
&#xD;
        -  Determine the therapeutic efficacy of this drug in inducing remissions in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine changes in lymphocyte subsets, immunoglobulin levels, serum cytokines, and&#xD;
           soluble cytokine receptor levels in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, dose-escalation study.&#xD;
&#xD;
      Patients receive BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5,&#xD;
      7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who achieve a complete response (CR) or&#xD;
      unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6&#xD;
      courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BL22 immunotoxin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the&#xD;
      cohort is expanded and a total of 12 patients are treated at that dose.&#xD;
&#xD;
      Patients are followed weekly for at least 1 month and then every 1-3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 95 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    protocol development and Amended protocol revision&#xD;
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of efficacy, safety, pharmacokinetics, immunogenicity.</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expansion of MTD</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BL22 immunotoxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antibody therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunotoxin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monoclonal antibody therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL22 immunotoxin</intervention_name>
    <description>BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody-drug conjugate therapy</intervention_name>
    <description>CD22 antibody, RFB4 on day 7</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunotoxin therapy</intervention_name>
    <description>tested for immunogenicity to CAT-8015 before each cycle and at end of study.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monoclonal antibody therapy</intervention_name>
    <description>administered intravenously over 30 minutes.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma&#xD;
             (including lymphoblastic lymphoma, Burkitt's lymphoma, and large cell lymphoma)&#xD;
&#xD;
               -  Not amenable to available curative therapies&#xD;
&#xD;
          -  Relapsed or refractory disease after at least 1 standard chemotherapy and 1 salvage&#xD;
             regimen&#xD;
&#xD;
          -  CD22 positive according to at least 1 of the following criteria:&#xD;
&#xD;
               -  More than 15% CD22-positive malignant cells by immunohistochemistry&#xD;
&#xD;
               -  More than 30% CD22-positive malignant cells by fluorescent-activated cell sorter&#xD;
                  analysis&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Prior CNS involvement allowed provided there is no current evidence of CNS malignancy&#xD;
&#xD;
          -  No CNS leukemia or lymphoma as manifested by any of the following:&#xD;
&#xD;
               -  Cerebrospinal fluid (CSF) WBC ≥ 5/mm^3 and confirmation of CSF blasts&#xD;
&#xD;
               -  Cranial neuropathies secondary to underlying malignancy&#xD;
&#xD;
               -  Radiologically detected CNS lymphoma&#xD;
&#xD;
          -  No isolated testicular ALL&#xD;
&#xD;
          -  Ineligible for or refused hematopoietic stem cell transplantation OR has disease&#xD;
             activity that prohibits the time required to identify a suitable stem cell donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  6 months to 24 years&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3 (12 to 24 years of age)&#xD;
&#xD;
          -  Lansky 40-100% (under 12 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3 *&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm^3 * NOTE: *Non-leukemic patients only&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  No active hepatitis B or C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal for age OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No serum neutralization of more than 75% of the activity of 1 µg/mL of study drug&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinically significant unrelated systemic illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other significant organ dysfunction that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or epoetin alfa)&#xD;
&#xD;
          -  Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT) allowed&#xD;
&#xD;
          -  More than 100 days since prior allogeneic HSCT&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided there has been no increase in the dose 1&#xD;
             week prior to and after study entry&#xD;
&#xD;
               -  Steroid taper allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
               -  Allowed in the past 3 weeks provided the volume of the bone marrow treated is &lt;&#xD;
                  10% AND the patients has measurable disease outside of the radiation port&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 30 days since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S. Wayne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <responsible_party>
    <name_title>Karen Kaucic, M.D.</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

